Other drug therapies for parkinson's disease

Principles of Treatment in Parkinson's Disease

Volumn , Issue , 2005, Pages 49-66

  Cersosimo, Maria Graciela ^a,b   Koller, William C ^c  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b HOSPITAL DE CLÍNICAS JOSÉ DE SAN MARTÍN   (Argentina)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33646710733     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-7506-5428-9.50007-X     Document Type: Chapter

References (72)

1. Ordestein L Sur la paralyse agitante et lasclérose en plaques generalisee 1867, 32. E Martinet, Paris.
2. Duvoisin RC Cholinergic-anticholinergic antagonism in parkinsonism. Arch Neurol 1967, 17:124-136.
3. Feldberg W Present views on the mode of action of acetylcholine in the central nervous system. Physiol Rev 1945, 25:596.
4. Doshay LJ, Constable K Artane therapy for parkinsonism: a preliminary study of results in one hundred and seventeen cases. JAMA 1949, 140:1317-1322.
5. Lang AE Treatment of Parkinson's disease agents others than levodopa and dopamine agonists: controversies and new approaches. Can J Neurol Sci 1984, 11:210-220. (suppl.).
6. Weiner WJ, Lang AE Movement Disorders: a Comprehensive Survey 1989, Futura Publishing, Mount Kisco, NY.
7. Koller WC Pharmacological treatment of parkinsonian tremor. Arch Neurol 1986, 43:126-127.
8. Cantello R, Riccio A, Gilli M, et al. Bornaprine vs placebo in Parkinson disease: double-blind controlled cross-over trial in 30 patients. Ital J Neurol Sci 1986, 7(1):139-143.
9. Martin WE, Loewenson RB, Resch JA, Baker AB A controlled study comparing trihexyphenidyl hydrochloride plus levodopa with placebo plus levodopa in patients with Parkinson's disease. Neurology 1974, 24:912-919.
10. Cooper JA, Sagar HJ, Doherty SM, et al. Different effects of dopaminergic and anticholinergic therapies on cognitive and motor function in Parkinson's disease: a follow-up study of untreated patients. Brain 1992, 115:1701-1725.
11. Friedman JH, Koller WC, Lannon MC, et al. Benztropine versus clozapine for the treatment of tremor in Parkinson's disease. Neurology 1997, 48:1077-1081.
12. Hauser RA, Ollanow CW Orobuccal dyskinesia associated with trihexyphenidyl therapy in a patient with Parkinson's disease. Mov Disord 1993, 8:512-514.
13. Birket-Smith E Abnormal involuntary movements induced by anticholinergic therapy. Acta Neurol Scand 1974, 50:801-811.
14. Hughes RC, Polgar JG, Weightman D, Walton JN Levodopa in parkinsonism: the effects of withdrawal of anticholinergic drugs. Brit Med J 1971, 2:487-491.
15. Goetz CG, Nausieda PA, Weines PH, Klawans HL Practical guidelines for drug holidays in parkinsonian patients. Neurology 1981, 31:641-642.
16. Jackson GG, Muldoon RL, Akers LW Serological evidence for prevention of influenza infection in volunteers by an anti-influenza drug, amantadine hydrochloride. Antimicrob Agents Chemother 1963, 3:703-707.
17. Schwab RS, England AC, Poskanzer DC, Young RR Amantadine in the treatment of Parkinson's disease. JAMA 1969, 208:1168-1170.
18. Factor SA, Molho ES Transient benefit of amantadine in Parkinson's disease: the facts about the myth. Mov Disord 1999, 14:515-517.
19. Shannon KM, Goetz CG, Carroll VS, Tanner CM, Klawans HL Amantadine and motor fluctuations in chronic Parkinson's disease. Clin Neuropharmacol 1987, 10:522-526.
20. Stoof JC, Booij J, Drukarch B Amantadine as N-methyl-D-aspartic acid receptor antagonist: new possibilities for therapeutic applications. Clin Neurol Neurosurg 1992, 94:s4-6.
21. Factor SA, Molho ES, Brown DL Acute delirium after withdrawal of amantadine in Parkinson's disease. Neurology 1998, 50:1456-1458.
22. Von Voigtlander PF, Moore KE Dopamine release from the brain in vivo by amantadine. Science 1971, 174:408-410.
23. Bailey EV, Stone TW The mechanism of action of amantadine in parkinsonism: a review. Arch Int Pharmacodyn Ther 1975, 216:246-262.
24. Gianutsos G, Chute S, Dunn JP Pharmacological changes in dopaminergic systems induced by long term administration of amantadine. Eur J Pharmacol 1985, 110:357-361.
25. Kornhuber J, Bormann J, Hubers M, Rusche K, Riederer P Effects of l-amino adamantanes at the MK-801 binding site of the NMDA receptor-gated ion channel: a human postmortem brain study. Eur J Pharmacol 1991, 206:297-300.
26. Sobolevski AI, Koshelev SG, Khodorov BI Interaction of memantine and amantadine with agonist inbound NMDA-receptor channels in acutely isolated rat hippocampal neurons. J Physiol 1998, 512(1):47-60.
27. Banplied TA, Boeckman FA, Aizenman E, Johnson JW Trapping channel block of NMDA receptors activated responses by amantadine and memantine. J Neurophysiol 1997, 77:309-323.
28. Brown F, Redfern PH Studies on mechanism of action of amantadine. Br J Pharmacol 1976, 58:561-567.
29. Metman LV, Del Dotto P, van den Munckhof P, et al. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology 1998, 50:1323-1326.
30. Goetz C New lessons from old drugs: amantadine and Parkinson's disease. Neurology 1998, 50:1211-1212.
31. Aoki FY, Sitar DS Clinical pharmacokinetics of amantadine hydrochloride. Clin Pharmacokinet 1988, 14:35-51.
32. Butzer JF, Silver DE, Sahs AL Amantadine in Parkinson's disease: a double-blind, placebo-controlled, crossover study with long-term follow-up. Neurology 1975, 25:603.
33. Fahn S, Isgreen WP Long term evaluation of amantadine and levodopa combination in parkinsonism by double-blind crossover analyses. Neurology 1975, 25:695-700.
34. Parkes JD, Baxter RC, Marsden CD, Rees JE Comparative trial of benzhexol, amantadine and levodopa in the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry 1974, 37:422-426.
35. Walker JE, Albers JW, Tourtellotte WW, et al. A qualitative and quantitative evaluation of amantadine in the treatment of Parkinson's disease. J Chronic Dis 1972, 25:149-182.
36. Savery F Amantadine and a fixed combination of levodopa and carbidopa in the treatment of Parkinson's disease. Dis Nerv Sys 1977, 38:605-608.
37. Fehling C The effect of adding amantadine to optimum levodopa dosage in Parkinson's syndrome. Acta Neurol Scand 1973, 49:245-251.
38. Millac P, Hasan I, Espir ML, Slyfield DG Treatment of parkinsonism with levodopa and amantadine. Lancet 1970, 2:720.
39. Callagham N, McIlroy M, O'Connor M Treatment of Parkinson's disease with levodopa and amantadine used as a single drugs and in combined therapy. Ir J Med Sci 1974, 143:67-78.
40. Marsden CD The drug therapy of early Parkinson's disease. The Comprehensive Management of Parkinson's disease 1988, 79-88. PMA Publishing, New York. M.B. Stern, H.H. Hurtig (Eds.).
41. Zeldowicz LR, Huberman J Long term therapy of Parkinson's disease with amantadine alone and combined with levodopa. Can Assoc J 1973, 109:588-593.
42. Chase TN, Engber TM, Mouradian MM Contribution of dopaminergic and glutamatergic mechanisms to the pathogenesis of motor response complications in Parkinson's disease. Adv Neurol 1996, 69:497-501.
43. Dunah AW, Wang Y, Yasuda RP, et al. Alteration in subunit expression, composition, and phosphorylation of striatal N-methyl-D-aspartate glutamate receptors in a rat 6-hydroxidopamine model of Parkinson's disease. Mol Pharmacol 2000, 57:342-352.
44. Metman LV, Del Dotto P, LePoole K, et al. Amantadine for levodopa induced dyskinesias: a 1-year follow-up study. Arch Neurol 1999, 56:1383-1386.
45. Del Dotto P, Pavese N, Gambaccini G, et al. Intravenous amantadine improves levodopa-induced dyskinesias: an acute double-blind placebo-controlled study. Mov Disord 2001, 16:515-520.
46. Snow BJ, Macdonald L, Mcauley D, Wallis W The effect of amantadine in levodopa induced dyskinesias in Parkinson's disease: a double-blind, placebo-controlled study. Clin Neuropharmacol 2000, 23(2):82-85.
47. Kornhuber J, Weller M, Schoppmeyer K, Riederer P Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties. J Neural Transm 1994, 43:91-104. (suppl.).
48. Danysz W, Parsons CG, Kornhuber J, Schmidt WJ, Quack G Amino adamantanes as NMDA receptor antagonists and antiparkinsonian agents: preclinical studies. Neurosci Biobehav Rev 1997, 21:455-468.
49. Lange KW, Kornhuber J, Riederer P Dopamine/glutamate interactions in Parkinson's disease. Neurosci Biobehav Rev 1997, 21:393-400.
50. Uitti RJ, Rajput AH, Ahlskog JE, et al. Amantadine treatment is an independent predictor of improved survival in Parkinson's disease. Neurology 1996, 46:1551-1552.
51. Kornhuber J, Weller M New therapeutic possibilities with low-affinity MNDA receptor antagonists. Nervenarzt 1996, 67(1):77-82.
52. Loffler H, Habermann B, Effendy I Amantadine induced livedo reticularis. Hautarzt 1998, 49:224-227.
53. Macchio GJ, Ito V, Sahgal V Amantadine-induced coma. Arch Phys Med Rehabil 1993, 74:1119-1120.
54. Vale JA, Maclean KS Amantadine-induced heart failure. Lancet 1977, 1(8010):548.
55. Pfeiffer RF Amantadine-induced vocal myoclonus. Mov Disord 1996, 11:104-106.
56. Shulman LM, Minagar A, Sharma K, Weiner WJ Amantadine-induced peripheral neuropathy. Neurology 1999, 53:1862-1865.
57. Knoll J Deprenyl [selegiline]: the history of its development and pharmacological action. Acta Neurol Scan 1983, 95:57-80.
58. Riederer P, Youdim MB, Rausch WD, et al. On the mode of action of L-deprenyl in the human central nervous system. J Neural Transm 1978, 43:217-226.
59. Parkinson's Study Group Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1989, 321:1364-1371.
60. Teravainen H Selegiline in Parkinson's disease. Acta Neurol Scand 1990, 81:333-336.
61. Myllyla VV, Sotaniemic KA, Vuorinen JA, Heinonen EA Selegiline as initial treatment in de-novo parkinsonian patients. Neurology 1992, 42:339-343.
62. Allain H, Pollak P, Neukirch HC Symptomatic effect of selegiline in de-novo parkinsonian patients: the French Selegiline Multicenter Trial. Mov Disord 1993, 8(1):s36-40.
63. Mally J, Kovacs AB, Slone TW Delayed development of symptomatic improvement by L-deprenyl in Parkinson's disease. J Neurol Sci 1995, 134:143-145.
64. Lees AJ, Shaw KM, Kohout LJ, et al. Deprenyl in Parkinson's disease. Lancet 1977, 2:791-795.
65. Lieberman AN, Gopinathan G, Neophytides A, Foo SH Deprenyl versus placebo in Parkinson's disease: a double-blind study. NY State J Med 1987, 87:646-649.
66. Golbe LI, Lieberman AN, Muenter MD, et al. Deprenyl in the treatment of symptom fluctuations in advanced Parkinson's disease. Clin Neuropharmacol 1988, 11:45-55.
67. Tetrud JW, Langston JW The effect of deprenyl (selegiline) in the natural history of Parkinson's disease. Science 1989, 245:519-522.
68. Parkinson Study Group Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects not requiring levodopa. Ann Neurol 1996, 39:29-36.
69. Olanow CW, Hauser RA, Gauger L, et al. The effect of deprenyl and levodopa on the progression of Parkinson's disease. Ann Neurol 1995, 38:771-777.
70. Palhagen S, Heinonan EH, Hagglund J, et al. Selegiline delays the onset of disability in de-novo parkinsonian patients: Swedish Parkinsons Study Group. Neurology 1998, 51:520-525.
71. Lees A, for the Parkinson's Disease Research Group of the U.K Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Br Med J 1995, 311:1602-1607.
72. Olanow CW, Myllyla VV, Sotaniemi KA, et al. Effects of selegiline on mortality in patients with Parkinson's disease: a meta-analysis. Neurology 1998, 51:825-830.